[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]
Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi
2010, Cilt 24, Sayı 3, Sayfa(lar) 161-165
[ Turkish ] [ Tam Metin ] [ PDF ]
Plasma Osteopontin Levels in the Patients with Ankylosing Spondylitis
Murat KARKUCAK1, Erhan ÇAPKIN1, Ayşe AKYÜZ2, Ahmet ALVER2, Ayşegül KÜÇÜKALİ TÜRKYILMAZ3, İrfan NUHOĞLU4, Nadim CİVAN4
1Karadeniz Teknik Üniversitesi Tıp Fakültesi, Fizik Tedavi ve Rehabilitasyon Anabilim Dalı, Trabzon, TÜRKİYE
2Karadeniz Teknik Üniversitesi Tıp Fakültesi, Biyokimya Anabilim Dalı, Trabzon, TÜRKİYE
3Rize Eğitim ve Araştırma Hastanesi, Fizik Tedavi ve Rehabilitasyon Anabilim Dalı, Rize, TÜRKİYE
4Karadeniz Teknik Üniversitesi Tıp Fakültesi, Endokrinoloji ve Metabolizma Hastalıkları Anabilim Dalı, Trabzon, TÜRKİYE
Keywords: Ankylosing spondylitis, osteopontin, TNF alpha, BASDAI

Objective: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease predominantly involving the axial skeleton. The aim of this study was to investigate the levels of plasma osteopontin (OPN) in relation with disease activity measures in patients with AS.

Materials and Methods: The study involved 108 AS patients, diagnosed according to the modified New York criteria and 65 healthy age and gender- matched adult controls. The disease activity; Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), spinal mobility; The Bath Ankylosing Spondylitis Metrology Index (BASMI), function; the Bath AS functional index (BASFI) and radiologic examination; the Bath Ankylosing radiologic index (BASRI) of patients with AS were recorded. Patients were divided into three groups. Patients in group 1 were taking non steroid anti inflammatory drugs (NSAIDs) and anti-tumor necrosis factor alpha (TNF-α), patients in group 2 were taking only NSAIDs and patients in group 3 were taking sulphasalazin and NSAIDs. The levels of plasma OPN, serum TNF alpha and Interleukin -6 were measured by ELISA.

Results: The AS patients had significantly higher plasma OPN levels (p=0.012). In the subgroups created according to the medical treatment and disease activity (BASDAI ≤4 and >4), there was no statically significant difference between groups with respect to plasma OPN levels. No significant correlation was determined between plasma OPN levels and parameters used to evaluate disease activity.

Conclusion: It was determined that plasma levels of OPN was significantly higher in patients with AS was than the controls. This was not related to the disease activity and medical treatment.


[ Turkish ] [ Tam Metin ] [ PDF ]
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]